Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Vivani Medical (TASE:BLWV), Inc. (NASDAQ:VANI), a small-cap healthcare company with a market capitalization of $77.6 million, announced the results of its 2025 Annual Meeting of Stockholders, held Tuesday. The company’s stock, currently trading at $1.30, has shown strong momentum with a 10% gain over the past week. According to a company statement based on an SEC filing, 37,097,099 out of 59,243,903 shares were represented at the meeting, constituting a quorum.InvestingPro analysis reveals several key insights about Vivani’s financial position, with 8 additional exclusive tips available for subscribers.
Shareholders elected all six nominees to the board of directors to serve until the 2026 annual meeting or until their successors are elected and qualified. The directors elected and the votes received were:
- Gregg Williams: 24,759,124 votes for; 561,720 withheld; 11,776,254 broker non-votes
- Aaron Mendelsohn: 24,814,324 votes for; 506,520 withheld; 11,776,254 broker non-votes
- Dean Baker: 24,920,589 votes for; 400,255 withheld; 11,776,254 broker non-votes
- Alexandra Popoff: 24,915,413 votes for; 405,431 withheld; 11,776,254 broker non-votes
- Adam Mendelsohn: 24,913,524 votes for; 407,320 withheld; 11,776,254 broker non-votes
- Daniel Bradbury: 24,950,672 votes for; 370,172 withheld; 11,776,254 broker non-votes
Shareholders also ratified the appointment of BPM LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 36,538,077 in favor, 98,316 against, and 460,706 abstaining, with no broker non-votes recorded on this proposal.
Additionally, shareholders approved, on a non-binding advisory basis, the compensation of Vivani’s named executive officers. The vote totaled 23,052,944 in favor, 594,065 against, and 1,673,835 abstaining, with 11,776,254 broker non-votes.
All information in this article is based on a press release statement and the company’s filing with the Securities and Exchange Commission.
In other recent news, Vivani Medical has announced a private placement, raising approximately $8.25 million to advance its drug implant development, including NPM-139 and NPM-115, which are designed for chronic weight management. The company also recently completed full enrollment for its Phase 1 LIBERATE-1 trial of the exenatide implant NPM-115, with results expected by mid-2025. H.C. Wainwright has maintained a Buy rating on Vivani Medical, with a stable price target of $4.00, reflecting confidence in the company’s progress and the potential of NPM-115.
Vivani Medical is also spinning off its subsidiary, Cortigent, to become an independent publicly traded company, focusing on neurostimulation devices. The spin-off is expected to be completed by the third quarter of 2025, subject to regulatory approvals. Additionally, Vivani has expanded its partnership with Okava Pharmaceuticals to develop a GLP-1 therapy for weight management in dogs, leveraging its NanoPortal technology.
In leadership changes, Vivani appointed Anthony Baldor as the new Chief Financial Officer, succeeding Brigid A. Makes, who will remain in an advisory role during the transition. These developments underscore Vivani’s strategic focus on advancing its pipeline and scaling operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.